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Abstract
Background: The association between oral contraceptive (OC) use and long-term mortality remains uncertain and
previous studies have reported conflicting findings. We aim to assess the long-term impact of OC use on all-cause
and cancer-specific mortality.
Methods: Out of 49,259 participants, we analysed data on 2120 (4.3%) women diagnosed with first primary breast
cancer between 1993 and 2012, in the Swedish Women’s Lifestyle and Health Study. Kaplan–Meier plots were used
to graph the hazard of mortality in association with oral contraceptives use, stage of disease and hormone receptors
status at diagnosis. Cox proportional hazard model were used to estimate hazard ratios (HR) between OC use and all-
cause mortality. The same association was studied for breast cancer-specific mortality by modelling the log cumulative
mortality risk, adjusting for clinical stage at diagnosis, hormone receptor status, body mass index and smoking.
Results: Among 2120 women with breast cancer, 1268 (84%) reported ever use of OC and 254 died within 10 years
of diagnosis. The risk of death for OC ever-users relative to never-users was: HR = 1.13 (95% CI: 0.66–1.94) for all-cause
mortality and HR = 1.29 (95% CI: 0.53–3.18) for breast cancer-specific mortality. A high percentage of women (42.9%)
were diagnosed at early stage disease (stage I).
Conclusions: Among women with primary breast cancer, OC ever-users compared to never- users did not have a higher
all-cause or breast cancer specific-mortality, after the adjustment of risk factors.
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Background
Breast cancer is the most common cancer in women
worldwide, with an estimated 1.7 million new cases diag-
nosed in 2012; representing about 12% of all new cancer
cases and 25% of all cancers in women [1]. Across all
countries in Europe, the breast is the leading cancer site
in women. Western Europe has the second highest
incidence rate of breast cancer worldwide; in Sweden,
the age-adjusted incidence rate is approximately
81.4/100,000 women [2, 3].
The association between oral contraceptive (OC) use
and the subsequent risk of breast cancer has been well-
studied. The International Agency for Research on
Cancer published a monograph in 2007, in which a
scientific specialist review panel agreed that there was
sufficient evidence for an association between OC use
and breast cancer risk in humans [4]. However, this
assessment found inconsistent results for women who
had ever used OC versus never-users. The increased risk
was only noted for women who were current or recent
OC users, particularly those who were less than 35 years
of age at diagnosis [4].
The more recent cohort studies which have examined
the association between ever OC use and all-cause mor-
tality or breast cancer-specific mortality among women
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with breast cancer, continue to report inconsistent re-
sults [5–11]. A number of cohort studies reported no
association [5, 6, 9–11], while other cohort studies
reported that OC use slightly reduces the risk of all-
cause mortality among women with breast cancer [7, 8].
For breast cancer-specific mortality, the majority of stud-
ies reported no association with OC use [6–8, 10, 12].
However, findings from the largest cohort to date, The
Nurses’ Health Study [5], which included 121,577 women,
found that OC use is associated with increased rates of
death due to breast cancer for women who have used OC
for 5 years or more compared to never-users (hazard ratio
(HR) = 1.26; 95% confidence interval (CI): 1.09 to 1.46.
OC is one of the most common used contraceptive
methods in Western Europe with an estimated 43.5% of
use among women of reproductive age [13]. In Sweden
in particular, an estimated 65 to 88% of women cur-
rently use or have used OCs [14–17]. Yet, studies on the
association between OC use and mortality among
women with breast cancer in Sweden are not available.
Given the public health implications and lack of consist-
ent findings, further study on the relationship between
OC use and breast cancer mortality is warranted.
The Swedish Women’s Lifestyle and Health (WLH)
cohort was designed to study the role of hormonal con-
traceptives in relation to breast cancer in Norway and
Sweden, populations with high prevalence of OC use
and high breast cancer incidence rates [14, 17]. Using
this population-based sample of Swedish women, we
examine the association between OC use on both all-
cause and breast cancer-specific mortality among




The WLH was designed to prospectively investigate the
association between lifestyle factors and cancer and car-
diovascular disease outcomes in women [14]. A total of
96,000 women born between 1943 and 1962 residing in
the Uppsala Health Care Region, who met the initial
inclusion criteria, were randomly selected from the
Swedish Population Registry and invited to participate
via a mailed questionnaire. During 1991–1992, 49,259
(51%) women responded to the baseline questionnaire
(Q1) and thus recruited into the WLH cohort. The ques-
tionnaires captured data on a variety of demographic,
lifestyle and health factors, including oral contraceptive
use (ever-used vs. never-used), height, weight and smok-
ing. Ethical approval was obtained from the Swedish
Data Inspection Board, the Regional Ethnical Committee
of Uppsala University, and the Ethical Committee of the
Karolinska Institutet.
Data linkage
The cohort data was linked to the Swedish Cancer
Registry database using personal identification number
(PIN) to identify all cases of breast cancer among partic-
ipants. The registry utilised three types of information:
1) Individual patient demographics: sex, age, place of
residence; 2) Medical data: tumour site, histological type,
Tumour-Node-Metastasis (TNM) (6th edition) stage,
basis of diagnosis, date of diagnosis, hormone receptors
(estragon and progesterone) and disease grade; 3)
Follow-up data: date of death, cause of death, date of
emigration. The Population Register is the civil registra-
tion of vital events, such as place and date of death,
burial site, and marriages for people born in Sweden or
emigrate in/out of Sweden. Information on death and
emigration were extracted from the Population Register
using PINs.
Case assessment and risk factors
All women diagnosed with an invasive, primary malig-
nant neoplasm of the breast (International Classification
of Diseases, tenth revision [13] (ICD-10)), from enrol-
ment until 31 December 2012 were considered for
analysis. We excluded all cases with breast cancer or a
second primary malignancies (n = 24) at the time of
recruitment to the study. Follow-up was calculated from
the date of breast cancer diagnosis to emigration, death
or study end point of 31 December 2013. A final dataset
comprised of 2120 cases of breast cancer was analysed.
Body mass index (BMI) was calculated as follows: weight
(kg) divided by the square of height, and the following
World Health Organization categories for BMI were used:
underweight, BMI < 18.5; normal, 18.5 ≥ BMI ≤ 24.9;
overweight, 25 ≥ BMI ≤ 29.9; obesity, BMI ≥ 30. Only 2%
(n = 42) of the study population were underweight, thus
we combined the underweight and normal category.
Smoking at Q1 was collected in three categories; current
smokers, former smokers, never smokers. Each patient
was assigned to one of four categories of (ER/PR) based
on their ER (estrogen) and PR (progesterone) receptors
status (ER+/PR+, ER−/PR+, ER+/PR-, ER−/PR-). Data on
TNM stage at diagnosis was converted into the clinical
five-level categories: 0, I, II, III & IV. The number of
patients diagnosed at more advanced stages were low and
therefore, stages II, III and IV were combined.
Statistical analysis
Person-time was calculated from the date of diagnosis
with breast cancer to death date or the last date of
follow up. Follow-up time was censored 10 years after
diagnosis. Kaplan–Meier plots were used to graph the
hazard of mortality in association with OC use, and on
potential confounders, where missing values were con-
sidered as a distinct category. Smoothed hazard plots
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were used to graph mortality from breast cancer in asso-
ciation with OC use and stage of disease. We estimated
Hazard Ratios (HR) and 95% confidence intervals (CIs)
for the association between OC use and the risk of death
from all causes (all-cause mortality) among women with
breast cancer, using Cox proportional hazards model and
adjusting for age at diagnosis, BMI, hormone receptors
status (ER/PR), stage of disease at diagnosis, and smoking.
Schoenfeld residuals were used to assess the proportional
hazards assumption. When the proportional hazards
hypothesis was not satisfied, we introduced a time func-
tion to model estimated time-varying HRs.
Cancer-specific mortality, generally known as ‘excess’
mortality due to cancer, was modelled as the difference
between all-cause mortality (observed) experienced by
cancer patients and the expected (background) mortality
of a comparable group from the general population. This
approach enabled population-level cancer-specific mor-
tality to be estimated in the absence of detailed informa-
tion on the cause of death. The background mortality
was derived from population life-tables that were
constructed by single year of age (0–99 years) and single
calendar year (1993–2013) and sex, for the entire popu-
lation of Sweden. Cancer-specific mortality was mod-
elled on the log cumulative hazard scale in a flexible
parametric framework [18, 19] using the stpm2 [20]
command in Stata version 14 [21], to predict the effect
of oral contraceptive use on breast cancer-specific mor-
tality after adjusting for age at diagnosis, BMI, hormone
receptors status (ER/PR), stage of disease at diagnosis,
and smoking. Data were incomplete for OC use and
three of the predictor variables.
The simplest way to analyse data with incomplete
variables is to exclude all records (cases) that are incom-
plete. This method is known as the complete-case ana-
lysis. Analysis of complete records may yield results that
could be substantially different from those that would be
obtained if complete information were collected on all
variables. Multiple imputation [22, 23] was used to
account for the incompleteness on OC, BMI, stage, and
ER/PR (Table 1), under the assumption that data were
missing at random (MAR). For each of the four possible
incomplete variables (OC use (n = 615; 29.0% missing),
stage (n = 495; 23.4% missing), BMI (n = 88;4.15% miss-
ing), or ER/PR receptor status (n = 415;19.6% missing),
we derived imputation models, that included the
remaining three incomplete variables in addition to the
complete variables for which no data were missing: age,
smoking, vital status and the cumulative survival time
(Nelson Aalen) [24]. We created 10 ‘completed’ data sets
from the ‘observed’ and the ‘imputed’ values. Analysis
models were fit for each completed dataset and results
were combined under Rubin’s rules [22]. Sensitivity
analyses were performed to assess the robustness of
results against departure from the MAR assumption
(results not shown). All analyses were carried out in
STATA version 14 [21].
Results
Demographics
Baseline characteristics for the population of 2120
Swedish women diagnosed with breast cancer before
enrolment are summarised in Table 1. The median fol-
low-up was 7.63 years. The mean age of breast cancer
diagnosis for this cohort was 55 years; 45% of women
were diagnosed within the age range of 45–54 years.
Among women with TNM stage, 42.9% were diagnosed
with stage I disease, 33.9% with stage II and 3.8% with
stage III and IV; therefore stages II, III & IV were com-
bined for subsequent analyses. Only 52 (2.5%) women
were identified with hormone receptor status ER−/PR+.
This receptor type was combined with ER+/PR- for ana-
lysis. Among women who reported OC use, 84.2%
(1268) reported ever use. Data for some women were
incomplete for the following variables: OC use (615
women, 29.1%), stage at diagnosis (495 women, 23.4%)
and receptor type (415 women, 19.6%) and BMI (88
women, 4.15%). The distribution of age and stage at diag-
nosis was similar for ever and never-users of OC. A higher
percentage of never-users of OC were above normal
weight (37.5%) compared to 24.9% of OC ever-users.
For a proportion of the 2120 women with breast
cancer, data were missing on OC use (615, 29.0%), stage
(495, 23.4), BMI (88, 4.15) and ER/PR receptor status
(415, 19.6%). Data on OC use was missing more often
on women diagnosed at (II, III & IV) stage of disease,
who were Normal-weight, and those diagnosed between
15 and 44 years of age (Table 1).
All-cause mortality
Patients with unknown OC use had the highest mortality
risk compared to ever and never-users. OC ever-users
had slightly higher mortality risk up to almost 3 years
after diagnosis, however mortality risk for never-users
increased and became higher than OC ever-users by 3.5
years after diagnosis (Fig. 1a).
Because of the incompleteness of data on OC use, and
three risk factors; BMI, stage, and ER/PR (Table 1), only
1014 (47.83%) of the study population could be analysed
in the multivariable model using the complete-case
analysis (Additional file 1).
After handling the unknowns for OC using multiple
imputation, the mortality risk for OC ever-users com-
pared to never-users was higher throughout the follow-
up period. Women diagnosed with breast cancer at
stages II, III & IV had higher risk of death up to at least
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10 years after diagnosis; before and after multiple imput-
ation (Fig. 2a and b). However, mortality risk for the
same period was much lower and with smaller difference
for those diagnosed at stage 0 and I (Fig. 2a and b). Risk
of death by hormone receptor status at diagnosis varied
considerably up to 4 years after diagnosis, for women
diagnosed with hormone receptor status ER−/PR- (higher
risk) than women with ER-PR+/ER + PR- or ER + PR+
(Fig. 3a and b).
All-cause mortality did not significantly differ between
OC ever-users and never-users (HR = 1.13, 95% CI:
0.66–1.94) after adjusting for covariates (Table 2).
Breast-cancer mortality
When the survival analysis was restricted to breast-can-
cer specific mortality only, HRs of similar magnitude
and significance to all-cause mortality were observed
(HR = 1.29; 95% CI: 0.53–3.18). (Table x).
OC ever-users had a higher breast-cancer specific
mortality risk compared to OC never-users (HR = 1.29,
95% CI: 0.53–3.18). This non-significant effect of OC
use was higher than that observed for all-cause
mortality (Table 2).
Discussion
We studied the risk of OC use on all-cause and breast
cancer-specific mortality among 2120 Swedish women
enrolled in a population-based cohort (WLH) and subse-
quently diagnosed with breast cancer between 1992 and
2012. Women who were ever-users of OC did not have
a higher all-cause or breast cancer-specific mortality as
compared to never-users.
Clinical stage at diagnosis, hormone receptor status,
BMI, year of diagnosis, smoking, and age were strong
confounders for the association between OC use and
mortality. The relationship between OC and mortality
Table 1 Characteristics of women with breast cancer, recruited to The Swedish Women’s Lifestyle and Health (WLH) (N = 2120), by
oral contraceptive use, 1993–2013
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would have been underestimated without accounting for
these variables. Our findings are in alignment with the
findings of a number of recently published studies which
have explored OC use and mortality and reported
hazard ratios of similar magnitude [6, 10, 25]. Results
were also similar to those of the Nurses’ Health Study,
which examined mortality in association with OC use up
to 36 years after diagnosis with breast cancer [5]. How-
ever, a retrospective study of a population-based cohort
of 4816 women found that ‘estrogen-progestin’ OC use
increased the risk of breast cancer mortality and all-
cause mortality (HR: 1.61; 95% CI: 1.14, 2.28) and (HR:
1.83; 95% CI: 1.30, 2.57), respectively [25]. It is possible
that differences in surveillance may bias the relationship
between OC use and breast cancer [17], with women
receiving OC more likely to attend breast cancer screen-
ing and wellness visits, thereby having lower mortality
rates. This potential bias is reduced in our study, as all
women in Sweden have undergone similar medical
surveillance and have the same access to medical care.
The finding related to hormone receptors (ER−/PR+ or
ER+/PR-) and increased risk of breast cancer mortality
was also consistent with other studies [26, 27].
The WLH cohort was designed to study the role of hor-
monal contraceptives in relation to breast cancer in
Norway and Sweden; populations with a high prevalence
of OC use and high breast cancer incidence rates [14, 17].
Before 1976, OC preparations were likely to contain high
doses of estrogens and/or progestins, which likely applies
to women in this birth cohort (born between 1943 and
(A) (B)
Fig. 1 Mortality risk from all causes, up to 10 years after diagnosis, by oral contraceptive use among women diagnosed with breast cancer in the
Swedish women’s lifestyle and health cohort. a without imputation of missing values for oral contraceptive use b after imputation of missing
values for oral contraceptive use
(A) (B)
Fig. 2 Mortality risk from all causes, up to 10 years after diagnosis, by stage of disease among women diagnosed with breast cancer in the
Swedish women’s lifestyle and health cohort. a without imputation of missing values for stage of cancer b after imputation of missing values for
stage of cancer
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1962) [4, 15]. The observation of a small non-significant
increased breast cancer risk among women who were
current/recent users of combined OCs (for example, those
containing an estrogen and a progestin) is compatible with
the “estrogen plus progestin” theory of breast cancer de-
velopment. This theory implies that the combination of
hormones induces more cell divisions than estrogen alone
[28]. Use of combined OCs directly increases levels of es-
trogen as well as progestogens, whereas progestin-only
pills only increase levels of progestogens without directly
raising estrogen levels. Estimates for breast cancer risk
among progestin-only pill users in this study could not be
estimated due to small sample sizes. Although present-day
OC hormonal formulations may differ from those used by
this cohort of women [14], it is nevertheless re-assuring
that this cohorts’ prior use of OC during their reproduct-
ive years is not likely to increase their risk of mortality.
The generalizability of our findings may be limited.
Our cohort consisted of Swedish women of the same
generation/similar birth cohort, who were well-educated
(over 80% with high school education). OC use was self-
reported prior to breast cancer diagnosis, however
estimates for these women were similar with what was
reported for the larger baseline cohort [14]. Information
on the use of hormone replacement therapy (HRT) was
collected at baseline (1991–92), and follow-up (2003).
The majority of baseline cohort (87.52%) and follow-up
cohort (88.29%) were pre-menopausal [14]. Only 5% of
cohort participants developed breast cancer after recruit-
ment to the cohort used HRT [17]. HRT has been asso-
ciated with a better prognosis of hormone receptor
positive breast cancer [29], thus HRT was excluded from
analysis. Missing data are a common problem in large
surveys, for which data are collected using extensive
mailed questionnaires such as The WLH. High levels of
incompleteness of OC use and the strong predictors of
mortality such as stage of disease, hormone receptor
type and BMI, complicate the analysis and can lead to
biased results [23, 24, 30]. We applied the method of
multiple imputation to account for missing data, includ-
ing all relevant cancer cases in the multivariable analysis.
Imputation models included all the variables in the ana-
lysis model, the cumulative survival time (Nelson Aalen)
[24] and vital status [24]. This method is only valid
under the assumption that data is missing at random
(MAR), which can never be validated with absolute cer-
tainty. However, including all predictors of missingness
and the outcome variables in the imputation model
improved the validity of the assumption of MAR.
A key strength of this study is the use of reliable and
validated data from a population-based cohort with al-
most complete follow-up for all participants up to 10
years after diagnosis, linked to the Swedish Cancer
Registry, with high levels of completeness [31]. We were
also able to adjust for the potential confounding effect of
stage at diagnosis and hormone receptor status (estrogen
and progesterone) in the estimated effect of OC use on
mortality. Our ability to adjust for receptor type is im-
portant given that ER- tumours have been demonstrated
to have a worse prognosis compared to ER+ tumours
[27]. The association between ever-use of OC and estro-
gen receptor-negative (ER-) breast cancer as compared
with ER+ cancer, however, is less clear; with a number of
past studies reporting strong associations [32–36], and
other studies concluding little or no difference [37–42].
The prospective design of this study also increases our
confidence for a lack of causal association found between
OC use and breast-cancer-specific and all-cause mortality.
(A) (B)
Fig. 3 Mortality risk from all causes, up to 10 years after diagnosis, by hormone status among women diagnosed with breast cancer in the Swedish
women’s lifestyle and health cohort. a without imputation of missing values for hormone status b after imputation of missing values for hormone status
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Another strength of this study is that use or non-use of
OCs is not likely to have influenced the timing of receipt
of a breast cancer diagnosis given that annual physical
examinations (or ‘check-ups’) are not regularly performed
or required in Sweden. Breast cancer screening initiatives
are organized outside medical doctors’ offices, and screen-
ing tests are carried out by nurses who refer patients for
follow-up with physicians when a pre-malignant or malig-
nant lesion is suspected.
Conclusion
Our results suggest that women with breast cancer who
were ever-users of OC, as compared to never-users of
OC, did not experience a higher all-cause or breast can-
cer-specific mortality, after the adjustment of risk fac-
tors. Our results relate to OC use at the study time, and
that we cannot rule out that current OCs may show a
different association. More research is needed on dur-
ation of contraceptive use, and biological underpinnings
behind OC use cessation in relation to breast cancer
mortality to clarify and support this evidence.
Additional file
Additional file 1: Hazard ratios of mortality (unadjusted and adjusted),
among women with breast cancer, in relation to OC, among 1014
women recruited to the WLH study, 1993–2013, using complete cases.
(DOCX 25 kb)
Abbreviations
BMI: Body mass index; ER: Estrogen; ER/PR: Hormone receptors status;
HR: Hazard ratios; OC: Oral contraceptives; PR: Progesterone; WLH: The
Swedish Women’s Lifestyle and Health cohort
Acknowledgements
Pouran Almstedt, Department of Medical Epidemiology and Biostatistics for
data management. Karolinska Institutet, Stockholm, Sweden.
Disclaimer
Where authors are identified as personnel of the International Agency for
Research on Cancer / World Health Organization, the authors alone are
responsible for the views expressed in this article and they do not
necessarily represent the decisions, policy or views of the International
Agency for Research on Cancer / World Health Organization.
Authors’ contributions
UN planned and prepared the draft of the paper. UN and DE carried out the
literature review. Data analysis was planned and implemented by UN. UN,
Table 2 Hazard ratios of mortality (unadjusted and adjusted), among women with breast cancer, in relation to OC, among 2120
women recruited to the WLH study, 1993–2013
*Models were adjusted for age at diagnosis, hormone receptor status, body mass index, smoking, stage at diagnosis and year of diagnosis
Nur et al. BMC Cancer          (2019) 19:807 Page 7 of 9
DE, DH and EW provided input and feedback on the content data analysis
and on the paper drafts. All authors read and approved the final manuscript.
Funding
Publication of this work have been funded by Qatar National Library. The
funding body had no role in the study design, data collection and analysis,
interpretation of the data and results, or in writing the manuscript.
Availability of data and materials
Data is available upon request using a signed application from the Karolinska
institutet website.
Ethics approval and consent to participate
Ethical approval was obtained from the Swedish Data Inspection Board, the
Regional Ethnical Committee of Uppsala University, and the Ethical
Committee of the Karolinska Institutet. All women gave informed consent




The authors declare that they have no competing interests.
Author details
1Department of Public Health, College of Health Sciences, QU Health, Qatar
University, P.O. Box, 2713, Doha, Qatar. 2Michigan Medical Advantage Group,
Ann Arbor, MI, USA. 3College of Human Medicine, Division of Public Health,
Michigan State University, East Lansing, MI, USA. 4Cancer Registry of Norway,
Institute of Population-Based Cancer Research, Oslo, Norway. 5Institute of
Basic Medical Sciences, University of Oslo, Oslo, Norway. 6International
Agency for Research on Cancer, Lyon, France.
Received: 3 February 2019 Accepted: 26 July 2019
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Mathers C, Rebelo M, Parkin
DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer incidence and
mortality worldwide: IARC CancerBase no. 11. Lyon: International Agency for
Research on Cancer. IARC; 2014. Available from: http://globocan.iarc.fr
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber
H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
3. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ,
Dinan M, McBroom AJ, Hasselblad V, Sanders GD, et al. Oral contraceptive use
and risk of breast, cervical, colorectal, and endometrial cancers: a systematic
review. Cancer Epidemiol Biomarkers Prev. 2013;22(11):1931–43.
4. IARC: Combined estrogen-progestogen contraceptives and combined
estrogen-progestogen menopausal therapy. In: IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans. 91. Lyon: International Agency
for Research on Cancer; 2007: 1–528.
5. Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA,
Hankinson SE, Speizer FE, Michels KB. Oral contraceptive use and mortality
after 36 years of follow-up in the Nurses’ health study: prospective cohort
study. Bmj. 2014;349:g6356.
6. Lu Y, Ma H, Malone KE, Norman SA, Sullivan-Halley J, Strom BL, Simon MS,
Marchbanks PA, McDonald JA, West DW, et al. Oral contraceptive use and
survival in women with invasive breast cancer. Cancer Epidemiol Biomarkers
Prev. 2011;20(7):1391–7.
7. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort
study with special reference to oral contraceptive use. Contraception. 2010;
82(3):221–9.
8. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality
among contraceptive pill users: cohort evidence from Royal College of general
Practitioners’ Oral contraception study. Bmj. 2010;340:c927.
9. Phillips KA, Milne RL, West DW, Goodwin PJ, Giles GG, Chang ET, Figueiredo
JC, Friedlander ML, Keegan TH, Glendon G, et al. Prediagnosis reproductive
factors and all-cause mortality for women with breast cancer in the breast
cancer family registry. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1792–7.
10. Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Moorman PG,
Kaufman JS, Cai J, Porter PL, Brinton LA, et al. Oral contraceptives and
survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol
Biomarkers Prev. 2007;16(9):1822–7.
11. Graff-Iversen S, Hammar N, Thelle DS, Tonstad S. Use of oral contraceptives
and mortality during 14 years’ follow-up of Norwegian women. Scand J
Public Health. 2006;34(1):11–6.
12. Wingo PA, Austin H, Marchbanks PA, Whiteman MK, Hsia J, Mandel MG,
Peterson HB, Ory HW. Oral contraceptives and the risk of death from breast
cancer. Obstet Gynecol. 2007;110(4):793–800.
13. United Nations Population Division. World Contraceptive Use 2005. New
York: Department of Economics and Social Affairs; 2006.
14. Roswall N, Sandin S, Adami HO, Weiderpass E. Cohort profile: the Swedish
Women's lifestyle and health cohort. Int J Epidemiol. 2017;46(2).
15. Ranstam J, Olsson H. Oral contraceptive use among young women in
southern Sweden. J Epidemiol Community Health. 1993;47(1):32–5.
16. Kopp Kallner H, Thunell L, Brynhildsen J, Lindeberg M, Gemzell Danielsson K.
Use of contraception and attitudes towards contraceptive use in Swedish
women--a Nationwide survey. PLoS One. 2015;10(5):e0125990.
17. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral
contraceptives and breast cancer risk: the Norwegian-Swedish Women's
lifestyle and health cohort study. Cancer Epidemiol Biomarkers Prev. 2002;
11(11):1375–81.
18. Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for
relative survival, with application in coronary heart disease. Stat Med. 2007;
26(30):5486–98.
19. Royston P, Sauerbrei W. Multivariable modeling with cubic regression
splines: a principled approach. Stata J. 2007;7(1):45–70.
20. Lambert PC, Royston P. Further development of flexible parametric models
for survival analysis. Stata J. 2009;9(2):265–90.
21. Statacorp. STATA statistical software. 13.0 ed. College Station: Stata
corporation; 2014.
22. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
23. Nur U, Shack LG, Rachet B, Carpenter JR, Coleman MP. Modelling relative
survival in the presence of incomplete data: a tutorial. Int J Epidemiol. 2010;
39(1):118–28.
24. Falcaro M, Nur U, Rachet B, Carpenter JR. Estimating excess hazard ratios
and net survival when covariate data are missing: strategies for multiple
imputation. Epidemiology. 2015;26(3):421–8.
25. Samson ME, Adams SA, Mulatya CM, Zhang J, Bennett CL, Hebert J, Steck
SE. Types of oral contraceptives and breast cancer survival among women
enrolled in Medicaid: a competing-risk model. Maturitas. 2017;95:42–9.
26. El Saghir NS, Assi HA, Jaber SM, Khoury KE, Nachef Z, Mikdashi HF, El-Asmar
NS, Eid TA. Outcome of breast Cancer patients treated outside of clinical
trials. J Cancer. 2014;5(6):491–8.
27. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan
NC, Paskett ED, McTiernan A, Hubbell FA, et al. Ethnicity and breast cancer:
factors influencing differences in incidence and outcome. J Natl Cancer Inst.
2005;97(6):439–48.
28. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki
AK, Ockene JK, Lane DS, Sarto GE, et al. Breast cancer after use of estrogen plus
progestin in postmenopausal women. N Engl J Med. 2009;360(6):573–87.
29. Rauh C, Schuetz F, Rack B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum
M, Heil J, Rom J, Sohn C, et al. Hormone therapy and its effect on the prognosis
in breast Cancer patients. Geburtshilfe Frauenheilkd. 2015;75(6):588–96.
30. Schottenfeld D, Winawer SJ: Cancers of the large intestine. In: Cancer
Epidemiology and Prevention. 2nd. Edited by D S, Jr FJ. Oxford: Oxford
University Press; 1996: 813–840.
31. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the
Swedish Cancer register: a sample survey for year 1998. Acta Oncol. 2009;
48(1):27–33.
32. Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL,
Slattery ML. Oral, injected and implanted contraceptives and breast cancer
risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer.
2007;121(11):2517–23.
33. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE,
Schoenberg JB, Brinton LA. Breast cancers among very young premenopausal
women (United States). Cancer Causes Control. 2003;14(2):151–60.
34. Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD. Risk factors for breast
cancer by oestrogen receptor status: a population-based case-control study.
Br J Cancer. 1989;59(1):119–25.
Nur et al. BMC Cancer          (2019) 19:807 Page 8 of 9
35. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE.
Risk factors for triple-negative breast cancer in women under the age of 45
years. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1157–66.
36. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast
cancer in women under age 50 years by estrogen and progesterone
receptor status: results from a case-control and a case-case comparison.
Breast Cancer Research. 2006;8(4):R39.
37. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the
risk of breast cancer according to estrogen- and progesterone-receptor
subgroup. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1053–60.
38. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG.
Hormone-related factors and risk of breast cancer in relation to estrogen
receptor and progesterone receptor status. Am J Epidemiol. 2000;151(7):703–14.
39. McCredie MR, Dite GS, Southey MC, Venter DJ, Giles GG, Hopper JL. Risk
factors for breast cancer in young women by oestrogen receptor and
progesterone receptor status. Br J Cancer. 2003;89(9):1661–3.
40. McTiernan A, Thomas DB, Johnson LK, Roseman D. Risk factors for estrogen
receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst.
1986;77(4):849–54.
41. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case-control
study of oral contraceptive use and incident breast cancer. Am J Epidemiol.
2009;169(4):473–9.
42. Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, Greenberg RS,
Hoover RN. A case-control study of breast cancer stratified by estrogen
receptor status. Am J Epidemiol. 1987;125(2):184–94.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Nur et al. BMC Cancer          (2019) 19:807 Page 9 of 9
